Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shivani Nanda

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Clinical Oncology|September 1, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in JapanDaisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, et al.
Lasers in Medical Science|October 4, 2018
Quantitative evaluation of skin shrinkage associated with non-invasive skin tightening: a simple method for reproducible linear measurement using microtattoosMurad Alam, Marisa Pongprutthipan, Shivani Nanda, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
WormPaths: <i>Caenorhabditis elegans</i> metabolic pathway annotation and visualizationMelissa D Walker, Gabrielle E Giese, Amy D Holdorf, et al.
The Lancet. Oncology|June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialNick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Genetics|June 12, 2021
WormPaths: Caenorhabditis elegans metabolic pathway annotation and visualizationMelissa D Walker, Gabrielle E Giese, Amy D Holdorf, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Lancet (London, England)|June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Blood Cancer Discovery|December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaDenis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Clinical Oncology|September 1, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in JapanDaisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, et al.
Lasers in Medical Science|October 4, 2018
Quantitative evaluation of skin shrinkage associated with non-invasive skin tightening: a simple method for reproducible linear measurement using microtattoosMurad Alam, Marisa Pongprutthipan, Shivani Nanda, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
WormPaths: <i>Caenorhabditis elegans</i> metabolic pathway annotation and visualizationMelissa D Walker, Gabrielle E Giese, Amy D Holdorf, et al.
The Lancet. Oncology|June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialNick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Genetics|June 12, 2021
WormPaths: Caenorhabditis elegans metabolic pathway annotation and visualizationMelissa D Walker, Gabrielle E Giese, Amy D Holdorf, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Lancet (London, England)|June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Blood Cancer Discovery|December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaDenis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
Pageof 4